Composition for growing intestinal lactic acid bacteria and preventing or treating depression containing mumefural

Abstract

The objective of the present invention is to provide a composition for the proliferation of intestinal lactic acid bacteria and / or for the prevention or treatment of depression. Additionally, the objective of the present invention is to provide a composition for the prevention or treatment of depression containing mumeprall. The mumeprall of the present invention has the effect of promoting the proliferation of Lactobacillus as an intestinal lactic acid bacterium, and also has the effect of inhibiting the secretion of corticosterone and promoting the secretion of serotonin.

Description

Technology Field

[0001] The present invention relates to a composition containing mumeprall for the proliferation of intestinal lactic acid bacteria and for the prevention or treatment of depression, and more specifically, to the use of mumeprall for the proliferation of intestinal lactic acid bacteria and for the prevention or treatment of depression. Background Technology

[0002] Lactic acid bacteria, which are abundant in fermented foods, coexist in the human digestive system and play a role in breaking down fiber and complex proteins into important nutrients. Live microorganisms that improve the host's intestinal microbial environment within the gastrointestinal tract of animals, including humans, and thereby have a beneficial effect on the host's health are collectively referred to as probiotics.

[0003] Lactic acid bacteria are bacteria that break down carbohydrates and use them to produce lactic acid; they are facultative or obligate anaerobic bacteria that thrive in low-oxygen environments. Lactic acid bacteria can be broadly classified into five genera: Streptococcus, Lactobacillus, Leuconostoc, Bifidobacteria, and Pediococcus.

[0004] Because lactic acid bacteria have beneficial effects on the health of the host, research on substances that promote the proliferation of lactic acid bacteria is actively underway.

[0005] Meanwhile, due to rapid social development and diversification, modern people are constantly exposed to various stressful situations, such as irregular eating habits and insufficient sleep. As a result of this continuous exposure to stress, the number of people suffering from mental illnesses, such as sleep disorders, anxiety disorders, or depression, is increasing. According to the 2016 Epidemiological Survey on the Prevalence of Mental Illness conducted by the Ministry of Health and Welfare, the lifetime prevalence of mental illness was found to be 25.4%.

[0006] In particular, depression is a serious illness characterized by a lack of motivation and feelings of sadness as primary symptoms, causing various cognitive and psychosomatic symptoms that lead to a decline in daily functioning and cause changes in emotions, thoughts, physical condition, and behavior. Depression is different from temporary sadness; it is not an expression of personal weakness or something that can be eliminated by willpower alone. In other words, depression is a brain and nervous system disorder caused by factors such as an imbalance of neurotransmitters, and it is regarded as a condition that requires medication to treat, rather than a simple psychological symptom.

[0007] Therefore, research on substances with preventive or therapeutic effects for depression is actively underway. Prior art literature

[65535] Republic of Korea Published Patent Application No. 10-2015-0062150 The problem to be solved

[0008] The objective of the present invention is to provide a composition having an effect of promoting the proliferation of intestinal lactic acid bacteria containing mumepraxal.

[0009] In addition, the objective of the present invention is to provide a composition for the prevention or treatment of depression containing mumeprall.

[0010] The purposes of the present disclosure are not limited to those mentioned above, and other purposes and advantages of the present disclosure not mentioned may be understood from the following description and will be more clearly understood from the embodiments of the present disclosure. Furthermore, it will be readily apparent that the purposes and advantages of the present disclosure can be realized by the means and combinations thereof set forth in the claims. means of solving the problem

[0011] The present invention provides a composition for the proliferation of intestinal lactic acid bacteria containing mumefural as an active ingredient.

[0012] The above-mentioned mumeprall may be represented by the following chemical formula 1:

[0013] .

[0014] [Chemical Formula 1]

[0015] The above intestinal lactic acid bacteria may be Lactobacillus.

[0016] The present invention may also provide a health functional food composition comprising the above composition.

[0017] The present invention may also provide a cosmetic composition comprising the above composition.

[0018] The present invention may also provide a composition for the prevention or treatment of depression containing mumefural as an active ingredient.

[0019] The above-mentioned mumeprall can inhibit the secretion of corticosterone and promote the secretion of serotonin. Effects of the invention

[0020] According to the present invention, a composition for the proliferation of intestinal lactic acid bacteria containing mumeprall and / or for the prevention or treatment of depression can be provided. Brief explanation of the drawing

[0021] FIG. 1 is a diagram showing a method for preparing an animal model of an allergic disease induced by ovalbumin in one embodiment of the present invention. Figure 2 is a figure showing the effect of increasing intestinal microorganisms by mumeprall in one embodiment of the present invention. FIG. 3 is a figure showing the effect of inhibiting corticosterone secretion by mumeprall in one embodiment of the present invention. Figure 4 is a figure showing the serotonin secretion-promoting effect by mumepraxal in one embodiment of the present invention. Specific details for implementing the invention

[0022] The term "Mumefural" in the present invention refers to a compound having the structure of Chemical Formula 1 below. Although Mumefural is known to possess pharmacological properties such as antiviral effects, its effects on the proliferation of intestinal lactic acid bacteria and the prevention, treatment, or improvement of depression-related diseases were not previously known and were identified for the first time by the inventors of the present invention.

[0023] .

[0024] [Chemical Formula 1]

[0025] The method of obtaining the above-mentioned mumeprall is not particularly limited and may be chemically synthesized using methods known in the art or commercially available materials may be used.

[0026] In addition, the compound may exist in a solvated or unsolved form, and may exist in a crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.

[0027] The term "prevention" in this invention refers to any act of suppressing or delaying depression-related diseases by administering a composition comprising the above-mentioned mumepraral or a pharmaceutically acceptable salt thereof.

[0028] The term "treatment" in this invention refers to any act in which the symptoms of a depression-related disease are improved or beneficially altered by the administration of a composition comprising the above-mentioned mumepraral or a pharmaceutically acceptable salt thereof.

[0029] The mumeprall of the present invention can reduce the expression of corticosterone increased by ovalbumin and increase the expression of serotonin reduced by ovalbumin.

[0030] The mumepral of the present invention can increase the amount of intestinal lactic acid bacteria, particularly Lactobacillus. In addition, the mumepral of the present invention can increase the amount of intestinal lactic acid bacteria, particularly Lactobacillus, which is reduced by ovalbumin.

[0031] The above composition may further include a pharmaceutically acceptable carrier, excipient, or diluent commonly used in the manufacture of pharmaceutical compositions, and the carrier may include a non-naturally occurring carrier. Specific examples of the carrier, excipient, and diluent may include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil.

[0032] The term "health functional food" in this invention refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body as defined in Act No. 6727 of the Health Functional Foods Act, and "functional properties" means obtaining effects useful for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body. Meanwhile, "health food" refers to a food that has active health maintenance or promotion effects compared to general food, and "health supplementary food" refers to a food intended for health support purposes; depending on the case, the terms health functional food, health food, and health supplementary food may be used interchangeably.

[0033] The mumeprall of the present invention may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods.

[0034] The health functional food composition of the present invention can be manufactured by methods commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art. Specifically, the health functional food composition may additionally include a physiologically acceptable carrier, the type of carrier is not particularly limited, and any carrier commonly used in the relevant technical field may be used.

[0035] In addition, the above-mentioned health functional food composition may include food additives such as preservatives, disinfectants, antioxidants, coloring agents, color-developing agents, bleaching agents, seasonings, sweeteners, flavorings, leavening agents, reinforcing agents, emulsifiers, thickeners, coating agents, gum bases, antifoaming agents, solvents, and improvers. The said additives may be selected according to the type of food and used in appropriate amounts.

[0036] Furthermore, the formulation of the above-mentioned health functional food may be manufactured without restriction as long as it is a formulation recognized as a food. The composition for health functional food of the present invention can be manufactured in various forms of formulations. Unlike general pharmaceuticals, it uses food as a raw material, offering the advantage of not causing side effects that may occur with long-term use of pharmaceuticals, and possesses excellent portability; therefore, the food of the present invention can be consumed as an adjuvant to enhance the effects of increasing intestinal lactic acid bacteria and preventing or improving depression.

[0037] The mumeprall of the present invention may be included in various weight percent of a health functional food composition if it can exhibit effects such as increasing intestinal lactic acid bacteria or preventing or improving depression. Specifically, it may be included in an amount of 0.00001 to 100 weight percent or 0.01 to 80 weight percent relative to the total weight of the health functional food composition, but is not limited thereto. When consumed over a long period for the purpose of health and hygiene, an amount below the above range may be included, and since there are no issues regarding safety, the active ingredient may also be used in an amount above the above range.

[0038] The cosmetic composition of the present invention may include other ingredients that are typically incorporated into cosmetic compositions. Examples include oil components, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, blood circulation promoters, cooling agents, purified water, etc.

[0039] The cosmetic composition of the present invention can be prepared in any formulation conventionally manufactured in the art, such as emulsions, creams, foundations, lotions, beauty serums, hair cosmetics, etc. Specifically, the cosmetic composition of the present invention includes formulations such as skin lotion, skin softener, moisture lotion, nourishing lotion, massage cream, nourishing cream, hand cream, moisture cream, essence, pack, soap, toner, milk lotion, gel, ointment, patch, cleansing foam, body cleanser, astringent, and spray. When the formulation of the present invention is a paste, cream, or gel, animal fiber, plant fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component. In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and particularly in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether. In the case where the formulation of the present invention is a solution or an emulsion, a solvent, a solvating agent, or an emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan. In the case where the formulation of the present invention is a suspension, liquid diluents such as water, ethanol, or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used as carrier components.In the case where the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative, or ethoxylated glycerol fatty acid ester, etc. may be used as a carrier component.

[0040] The mumeprall of the present invention may be included in a cosmetic composition in various weight percent if it can exhibit effects such as increasing intestinal lactic acid bacteria or preventing or improving depression. Specifically, it may be included in an amount of 0.00001 to 100 weight percent or 0.01 to 80 weight percent relative to the total weight of the cosmetic composition, but is not limited thereto. When applied for a long period for the purpose of health and hygiene, an amount below the above range may be included, and since there are no issues regarding safety, the active ingredient may also be used in an amount above the above range.

[0042] The present invention will be explained in more detail below through examples and experimental examples. However, these examples and test examples are intended to illustrate the invention, and the scope of the present invention is not limited to these examples and test examples.

[0044] Example 1: Preparation of allergy animal model and oral drug administration (In vivo)

[0045] The experimental animals used in this experiment were 5-week-old mice (Balb / c). Ovalbumin (OVA) was administered intraperitoneally on days 14 and 28, and sensitization was performed using 1% OVA aerosol three times a week for 4 to 8 weeks. To observe the allergy-relieving effect, mumefural (MF) or dexamethasone (Dexa) was administered orally three times a week for 5 to 8 weeks. The method of preparing the animal model is shown in Figure 1.

[0047] Example 2: Measurement of microbial distribution in stool

[0048] To confirm the effect of mumeprall on increasing intestinal microorganisms, the distribution of intestinal microorganisms was investigated, and the results are shown in Figure 2. Changes in intestinal microorganisms were observed when 400 mg / kg of mumeprall was orally administered to normal mice and allergy-induced mice for 5 to 8 weeks. In Figure 2, Con represents the control group, Con+MF represents the control group orally administered mumeprall, OVA represents the allergy-induced group, and OVA+MF represents the allergy-induced group orally administered mumeprall. As shown in Figure 2, it can be confirmed that the amount of Lactobacillus microorganisms increased due to the administration of mumeprall.

[0050] Example 3: Measurement of blood corticosterone and serotonin levels

[0051] Corticosterone content was measured by separating blood and using an ELISA kit.

[0052] Plasma of each standard and samples from each group (Con, Con+MF, OVA, OVA+MF) was added to an antibody-coated plate and left for 1 hour. Afterward, a secondary antibody and a chromogen substrate were added, and measurements were taken at 450 nm on a microplate. The results are shown in Figures 3 and 4. In Figures 3 and 4, MF200 and MF400 refer to the administration of 200 mg / kg and 400 mg / kg of mumeprall, respectively. As shown in Figures 3 and 4, it was confirmed that the content of corticosterone decreased and the content of serotonin increased upon the administration of mumeprall.

[0054] The following is an example of a preparation for the composition of the present invention.

[0056] Preparation Example

[0057] <Preparation Example 1> Preparation of a pharmaceutical formulation

[0059] 1. Preparation of powders

[0060] Mumepral 200 mg

[0061] 2 g lactose

[0062] The above ingredients were mixed and filled into an airtight bag to manufacture a powder.

[0064] 2. Preparation of tablets

[0065] Mumepral 1 mg

[0066] 100 mg corn starch

[0067] 100 mg lactose

[0068] Magnesium stearate 2 mg

[0069] After mixing the above ingredients, tablets were manufactured by compressing them according to the conventional method of manufacturing tablets.

[0071] 3. Manufacture of capsules

[0072] Mumepral 1 mg

[0073] 100 mg corn starch

[0074] 100 mg lactose

[0075] Magnesium stearate 2 mg

[0076] After mixing the above ingredients, a capsule was manufactured by filling it into a gelatin capsule according to a conventional method for manufacturing capsules.

[0078] 4. Preparation of pills

[0079] Mumepral 5 mg

[0080] 2 g lactose

[0081] 1 g glycerin

[0082] 1 g xylitol

[0083] After mixing the above ingredients, the product was prepared according to a conventional method so that each pill weighed 4 g.

[0085] 5. Preparation of granules

[0086] Mumepral 5 mg

[0087] Soybean extract 50 mg

[0088] 200 mg glucose

[0089] 600 mg starch

[0090] After mixing the above ingredients, 100 mg of 30% ethanol was added and dried at 60°C to form granules, which were then filled into a bag.

[0092] <Preparation Example 2> Preparation of food

[0094] 1. Preparation of soups and gravies

[0095] 0.1 to 5.0 parts by weight of the mumepramal of the present invention was added to 100 parts by weight of soup or meat broth to produce a meat processing product for health promotion, a soup or meat broth for noodles.

[0097] 2. Preparation of ground beef

[0098] Health-promoting ground beef was prepared by adding 1 part by weight of the mumefralk of the present invention to 100 parts by weight of ground beef.

[0100] 3. Manufacture of dairy products

[0101] One part by weight of the mumeprall of the present invention was added to 100 parts by weight of milk, and various dairy products such as butter and ice cream were manufactured using the milk.

[0103] <Preparation Example 3> Preparation of a beverage

[0104] 1. Preparation of health drinks

[0105] A health drink was manufactured by homogeneously mixing 50 mg of the dried plum of the present invention with auxiliary ingredients such as liquid fructose (0.5 parts by weight), oligosaccharide (2 parts by weight), sugar (2 parts by weight), salt (0.5 parts by weight), and water (75 parts by weight), sterilizing the mixture at a moment, and then packaging it in a small packaging container such as a glass bottle or a PET bottle.

[0107] 2. Preparation of vegetable juice

[0108] A vegetable juice for health promotion was prepared by adding 50 mg of the mumeprall of the present invention to 1,000 ml of tomato or carrot juice.

[0110] 3. Preparation of fruit juice

[0111] A health-promoting fruit juice was prepared by adding 1 mg of mumeprall of the present invention to 1,000 ml of apple or grape juice.

[0113] <Preparation Example 4> Preparation of external skin agent

[0114] 1. Preparation of cosmetic lotion using Mumeprall

[0115] 1 kg of cosmetic lotion containing mumepral was prepared with the content shown in Table 1 below.

[0116]

[0117] As a specific manufacturing method, substances 2, 3, 4, and 8 were sequentially added to substance 11 in Table 1 above into a reaction vessel and stirred to dissolve them, and then substance 5 was heated to about 60°C to dissolve it. Next, substance 10 was added to the reaction vessel and dissolved, and then added to substance 11. Finally, substances 1, 6, 7, and 9 were added and stirred thoroughly, and then aged at 25°C for 3 days to produce the cosmetic water of the present invention.

[0119] 2. Manufacture of a nourishing lotion containing mumepral

[0120] 1 kg of the hydrosome nourishing lotion containing the above-mentioned mumeprall was prepared with the content of Table 2 below.

[0121]

[0122] As a specific manufacturing method, substances numbered 10, 11, 13, and 16 in Table 2 above were mixed and stirred while being heated to between 80 and 85°C and then introduced into the manufacturing unit. After applying an emulsifier, substances 2, 3, 4, 5, 6, 7, 8, 9, and 12 were heated and melted to between 80 and 85°C and then emulsified. Once the emulsification was complete, the mixture was stirred using a stirrer and cooled to 50°C, then substance 15 was introduced. After cooling to 45°C, substance 14 was introduced, and at 35°C, substance 1 was introduced and cooled to 25°C. Finally, the mixture was aged at 25°C for 3 days to produce the nutritional lotion of the present invention.

[0124] 3. Preparation of a nourishing serum containing mumeprax

[0125] 1 kg of the hydrosome nutritional serum containing the above-mentioned mumeprall was prepared with the content of Table 3.

[0126]

[0127] As a specific manufacturing method, substances 2, 3, and 5 in Table 3 above were mixed and stirred while being heated to between 40 and 45°C and then introduced into the manufacturing unit, followed by the application of an emulsifier, substances 4, 6, and 7 were introduced into the manufacturing unit and emulsified. Once emulsification was complete, the mixture was cooled to 35°C while stirring with a stirrer, substance 1 was introduced and cooled to 25°C, and then aged at 25°C for 3 days to produce the nutritional serum of the present invention.

[0129] 4. Preparation of essence using Mumepral

[0130] 1 kg of the hydrosome essence containing the above-mentioned mumeprall was prepared with the content of Table 4 below.

[0131]

[0132] As a specific manufacturing method, substances 2, 3, 4, 5, and 6 of Table 4 above were homogenized at a constant temperature to prepare a nonionic amphiphilic lipid. This nonionic amphiphilic lipid was mixed with substances 1, 7, 8, and 14, homogenized at a constant temperature, and passed through a microfluidizer. Subsequently, substance 9 was heated to 50–60°C, slowly added, homogenized, and then passed through the microfluidizer again. Afterward, substances 10, 11, 12, and 13 were added, dispersed, stabilized, and aged at 25°C for 3 days to prepare the essence of the present invention.

[0134] As described above, it was confirmed that the manufactured cosmetic composition is highly effective in skin recovery, wrinkle improvement, whitening, and skin texture refinement.

[0136] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single unit may be implemented in a distributed manner, and components described as distributed may likewise be implemented in a combined form.

[0137] The scope of the present invention is defined by the claims, and all modifications or variations derived from the meaning and scope of the claims and equivalent concepts thereof should be interpreted as being included within the scope of the present invention.

Claims

Claim 1 A health functional food composition for promoting the growth of intestinal lactic acid bacteria containing mumefural as an active ingredient. Claim 2 A health functional food composition for promoting the growth of intestinal lactic acid bacteria according to claim 1, wherein the above-mentioned mumepraral is represented by the following chemical formula 1. [Chemical Formula 1] Claim 3 A health functional food composition for promoting the proliferation of intestinal lactic acid bacteria according to claim 1, wherein the intestinal lactic acid bacteria is Lactobacillus. Claim 4 delete Claim 5 A cosmetic composition for promoting the growth of intestinal lactic acid bacteria containing mumefural as an active ingredient. Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 delete

Images